With respect to preclinical AD, a variety of blood-based biomarkers–p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40––and Aβ pathology were compared in at-risk individuals (divided into two groups, over and under 65 years old) [73]. Here, NEFL is linked to Alzheimer disease.